30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
The prevalence of comorbidities and functional impairment among elderly patients may enhance the risk of operation-related complications, but the importance of these conditions in elderly patients undergoing thoracic surgery remains unclear. 4 key findings →
Participants: 120 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
As elderly populations grow, dementia detection in the community is increasingly needed. 4 key findings →
Participants: 249 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The burden perceived by caregivers of patients with dementia is a fundamental prognostic aspect in the history of the disease. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
To investigate the cognitive capacities of a cohort of ischaemic or haemorrhagic stroke survivors and to identify the clinical determinants of post-stroke cognitive impairment, we evaluated 237 patients admitted to a Stroke Unit (mean age 59; SD=12.7). 4 key findings →
Participants: 237 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Understanding preclinical transitions to impairment in cognitive abilities associated with risks for functional difficulty and dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) provides ratings of an individual's changes in everyday cognitive functions during the previous 10 years. 4 key findings →
Participants: 399 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We sought to investigate whether the seropositivity of common infections was associated with cognitive function. 4 key findings →
Participants: 106 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Gait abnormalities are associated with cognitive decline, and reduced gait speed and gait asymmetry are markers of cognitive decline and increased fall risk in patients with established DLB. 5 key findings →
Design: cross-sectional Participants: 63 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 500 dementia patients (mean age 78.3 ± 7.2 years), Kaplan-Meier analysis revealed significantly earlier pneumonia onset in severe dementia patients (log-rank P < 0.001), with Cox regression showing that severe dementia conferred triple the pneumonia risk (hazard ratio [HR] = 3.01, 95% confidence interval [CI]: 2.15-4.21) and that swallowing dysfunction independently increased the hazard ratio 3.45-fold (95% CI: 2.61-4.55); aspiration pneumonia accelerated cognitive decline (β = -2.35, 95% CI: -3.12 to -1.58). 4 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During follow-up 20 SCD and 99 MCI patients developed dementia. 5 key findings →
Participants: 184 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Serum beta-synuclein level was progressively increased in the AD continuum across the preclinical, MCI and dementia stages compared with controls and was correlated with serum pTau181 (r=0.710), NfL (r=0.494) and GFAP concentrations (r=0.621, p<0.001 for all). 5 key findings →
Participants: 56 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 1013 participants, 847 screened positive on MoCA (70.4% mild, 13.2% moderate) for cognitive impairment and were assessed further for other domains of ICMR-MUDRA toolbox. 5 key findings →
Design: cross-sectional Participants: 1,013 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundHigh blood pressure has been associated with dementia prevalence and incident. 3 key findings →
Participants: 1,435 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The speech assessment was feasible, indicated by 91.6% adherence and usability scores of 86.0 ± 9.9. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Smartphones have potential as cognitive aids for adults with cognitive impairments. 1 key finding →
Participants: 53 Evidence: low
Full summary, score breakdown and related studies → Original source
Recent evidence has suggested a role for soluble oligomeric Abeta species in the pathology of Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We studied the usefulness of measuring volumes of the hippocampus, amygdala and frontal lobes with coronal magnetic resonance imaging (MRI) scans in the diagnosis of early Alzheimer's disease (AD). 4 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We have previously shown that beta-band EEG activity is related to attentional modulation in the visual system of cats and humans. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The hippocampus is one of the most well studied structures in the human brain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We studied whether Mini-Mental State Examination (MMSE) norms for detecting dementia in elderly outpatients vary according to educational attainment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Postmortem demonstration of increased expression of biologically active S100B in Alzheimer's disease (AD) and its relation to progression of neuropathological changes across the cortical regions suggests involvement of this astrocytic cytokine in the pathophysiology of AD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This aim of this study was to assess the clinical utility of the Montreal Cognitive Assessment (MoCA) as a screening instrument for cognitive impairment in patients referred to a memory clinic, alone and in combination with the Mini-Mental State Examination (MMSE). 4 key findings →
Participants: 150 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is accompanied by smell dysfunction, as measured by psychophysical tests. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Similar to Alzheimer's disease (AD), dementia with Lewy bodies (DLB) is characterized by a profound degeneration of cortically-projecting cholinergic neurons of the basal forebrain (BF) and associated depletion of cortical cholinergic activity. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The usefulness of the Mini-Mental State Examination (MMSE) as a screening test for identifying cognitive impairment in patients with multiple sclerosis (MS) has been questioned because many patients who score above the suggested cutoff score of 24 exhibit severe focal or global cognitive deficits. 4 key findings →
Participants: 85 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events